Medicines, reimagined
Targeted + immunotherapy to transform patient lives.
Our goal is deliver innovative drugs that shift the paradigm for patients living with complex diseases
We are a team of experienced drug developers, passionate about advancing medicines that shift the treatment paradigm. We are currently focused on strategies to modulates B cells, a type of lymphocytes, that play a pivotal role in immunity. B cells have recently been shown clinically to improve survival outcomes in multiple tumors, yet they remained unexplored. We are advancing a deep pipeline of drugs that modulate B cells, with our lead molecule in the clinics for treatment of solid cancers.
We leverage a patented quantum mechanics platform to optimize efficacy and safety of our drugs.
We are clinical stage.
Combining targeted and immuno-therapy in a single molecule
We are pioneering small molecules that act as targeted therapeutics as well as modulate the immune response. Our clinical stage molecule, AT1965, inhibits CMTR2, a novel target, in cancer cells, and recruits a B cell immune response. This dual and novel mechanism of action confers durable efficacy. AT-1965 regressed hard-to-treat solid tumors when given as monotherapy in preclinical studies and was synergistic with immune checkpoint inhibitors.